Grupo de Imaxe Molecular e Física Médica
MIMP
Hospital Vall d'Hebron
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (11)
2024
-
Preclinical characterization of endotoxin-induced uveitis models using OCT, PET/CT and proteomics
International Journal of Pharmaceutics, Vol. 662
2023
-
Description of a different quantification method for amyloid burden (burdenDPD) and validation of SPECT/CT in cardiac amyloidosis
Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 3, pp. 171-177
1989
-
Circulating CA 15-3 antigen levels in non-mammary malignancies
British Journal of Cancer, Vol. 59, Núm. 2, pp. 283-286
-
Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases
Breast Cancer Research and Treatment, Vol. 13, Núm. 2, pp. 123-133
-
Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease
Cancer, Vol. 64, Núm. 8, pp. 1674-1681
1986
-
Circulating CA 15.3 levels in breast cancer. Our present experience.
The International journal of biological markers, Vol. 1, Núm. 2, pp. 89-92
-
Evaluation of specific antigen and prostatic acid phosphatase specificity. Study of false values.
The International journal of biological markers, Vol. 1, Núm. 3, pp. 141-146
-
Serum CA 19.9 levels in patients with non tumoral pathologies. Our experience in 892 cases
Bulletin du Cancer, Vol. 73, Núm. 3, pp. 256-259
1985
-
EL ANTIGENO PROSTATICO ESPECIFICO. NUEVO MARCADOR TUMORAL
Medicina Clinica, Vol. 85, Núm. 19, pp. 801-804
-
ESTUDIO DE LA COLIGLICINA Y LA SULFOLITOCOLIGLICINA POSPRANDIALES EN LAS HEPATOPATIAS FOCALES Y DIFUSAS
Medicina Clinica, Vol. 85, Núm. 16, pp. 653-655
1984
-
CA125 seric levels in non malignant pathologies
Bulletin du Cancer